What is it used for?
ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- vorinostatvorinostat
- Form and strength
- CAPSULE · 100 mgCAPSULE · 100 mg
- Manufacturer / applicant
- MERCK SHARP & DOHME LLCMERCK SHARP & DOHME LLC
Capsules: 100 mg white, opaque, hard gelatin capsules with "568" over "100 mg" printed within radial bar in black ink on the capsule body.Capsules: 100 mg white, opaque, hard gelatin capsules with "568" over "100 mg" printed within radial bar in black ink on the capsule body.
Safety and clinical review
- ThromboembolismThromboembolism
- MyelosuppressionMyelosuppression
- Gastrointestinal ToxicityGastrointestinal Toxicity
- HyperglycemiaHyperglycemia
- Clinical Chemistry AbnormalitiesClinical Chemistry Abnormalities
- Severe Thrombocytopenia when Combined with Other Histone Deacetylase (HDAC) InhibitorsSevere Thrombocytopenia when Combined with Other Histone Deacetylase (HDAC) Inhibitors
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is ZOLINZA used for?
ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of ZOLINZA should I ask about?
CAPSULE · 100 mgCAPSULE · 100 mg
Read the primary sourceWhat determines the price of ZOLINZA?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using ZOLINZA?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.